Last reviewed 2026-04-20 · How we verify

400mg

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.'s 400mg drug, currently marketed for acid indigestion relief, holds a position in a competitive therapeutic area. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity, enhancing the drug's competitive edge. The primary risk lies in the potential increase in competition post-patent expiry, which could impact market share and revenue.

At a glance

Approved indications

• Acid Indigestion Relief
• Upset Stomach Relief

Common side effects

No common side effects on file.

Key clinical trials

• The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. (NA)
• Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
• A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma (PHASE1)
• Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (PHASE2)
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) (PHASE2)
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (PHASE3)
• The Body's Affect on Vitamin C (PHASE1)
• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.